Fanconi anemia drug market is anticipated to grow at a significant CAGR during the forecast period. Fanconi anemia is a rare inherited disease. It mainly affects the bone marrow and results in decreased production of all types of blood cells. Additionally, it is the most common inherited form of aplastic anemia and is different from fanconi syndrome. The major factor driving the demand for Fanconi anemia drugs is the increasing prevalence of the fanconi anemia across the globe.
According to the National Center for Biotechnology Information (NCBI), Fanconi anemia is a very rare type of anemia with a prevalence rate of an average of 1 out of 136,000 newborns. Additionally, it varies from 1 in 100,000 to 250,000 births. Furthermore, half the patients are diagnosed before age 10 while about 10% are diagnosed as adults. Moreover, the condition is more common among people of Ashkenazi Jewish descent, the Roma population of Spain, and black South Africans. Hence, the increasing prevalence of fanconi anemia is driving the demand for fanconi anemia drugs for treatment which in turn is driving the growth of the market.
Some major players in the market include Abeona Therapeutics Inc., Genethon SA, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Rocket Pharmaceuticals, Inc. announced the positive clinical updates from its ongoing Phase 2 registrational trials for Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) and its ongoing Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the 63rd American Society of Hematology (ASH) Annual Meeting.
To Request a Sample of our Report on Fanconi Anemia Drug Market: https://www.omrglobal.com/request-sample/fanconi-anemia-drug-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Abeona Therapeutics Inc., Genethon SA, and Novartis International AG, among others.
Fanconi Anemia Drug Market Report by Segment
By Type
- Eltrombopag Olamine
- EXG-34217
- Fancalen
- Others
By Application
- Hospital
- Clinic
- Others
A full Report of Fanconi Anemia Drug Market is Available @ https://www.omrglobal.com/industry-reports/fanconi-anemia-drug-market
Fanconi Anemia Drug Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
